drugset
drugset / Trial / NCT01480648

Single Rising Dose Study of BI 144807 Powder in Bottle in Healthy Male Volunteers

NCT01480648 ↗

Phase 1 Completed 74 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

This first-in-man trial forms the basis for potential clinical development of BI 144807 in the indications of asthma and allergic rhinitis. The safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising doses of BI 144807 will be assessed in healthy male volunteers.

Timeline

Start
2011-11
Primary completion
2012-02
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject LAZUCIRNON Small molecule 1 mg Oral
Subject LAZUCIRNON Small molecule 1200 mg Oral

Indications

No indication recorded.